CAS Number327036-89-5
Synonymscc-646; NP12; TDZD-8; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
Molecular FormulaC10H10N2O2S
Molecular Weight222.26
Purity≥95 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point335.5±35.0 °C at 760 mmHg
Melting Point63-64.4ºC
Appearancesolid
EINECS0
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 327036-89-5 |
| Catalog No. | 2A-0137075 |
| Chinese Name | 4-苯甲基-2-甲基-1,2,4-噻二唑烷-3,5-二酮 |
| Synonyms | cc-646; NP12; TDZD-8; 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione |
| Molecular Formula | C10H10N2O2S |
| Molecular Weight | 222.26 |
| Purity | ≥95 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 335.5±35.0 °C at 760 mmHg |
| Melting Point | 63-64.4ºC |
| Appearance | solid |
| Water Solubility | DMSO: 18 mg/mL |
| Storage Condition | 2-8°C |
| Application | TDZD-8 is an inhibitor of GSK-3β with an IC50 of 2 μM; TDZD-8 has a weak effect on Cdk-1/cyclin B, CK-II, PKA and PKC, with IC50 values >100 μM. |
| EINECS | 0 |
| HTC | 2934999090 |
| UN(IATA) | 0 |
| MDL Number | MFCD04973552 |
| SMILES | S1N(C(=O)N(C1=O)Cc2ccccc2)C |
| InChI | 1S/C10H10N2O2S/c1-11-9(13)12(10(14)15-11)7-8-5-3-2-4-6-8/h2-6H,7H2,1H3 |
| InChI Key | JDSJDASOXWCHPN-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | transportation |
| MSDS | msds/137075_1_327036_89_5.pdf |
| Bioactivity | TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM. Related Catalog Signaling Pathways >> PI3K/Akt/mTOR >> GSK-3 Signaling Pathways >> Stem Cell/Wnt >> GSK-3 Research Areas >> Cancer Target GSK-3β:2 μM (IC50) In Vitro TDZD8 results in a significant decline of cellular ATP levels in PC-3 cells. TDZD8 (10 μM) treatment also triggers a drastic autophagy response and AMPK activation in PC-3 cells. Furthermore, TDZD8 (10 μM) reduces mTOR phosphorylation levels at the S2448 site. In addition, TDZD8 (10 μM) induces LKB1 nuclear-cytoplasm translocation[3]. In Vivo TDZD-8 (TDZD8, 1 or 2 mg/kg, i.p.) both reduces the induction of p-DARPP32 following chronic L-dopa treatment in parkinsonian animals. TDZD8 treatment of 21 days induces a significant reduction in PKA expression in rats with established dyskinesia. Moreover, TDZD8 reduces FosB mRNA level in the striatum and lowers the expression of PPEB mRNA to similar levels as in 6-OHDA-lesioned rats without treated with L-dopa. The decrease in dyskinesia induced by TDZD8 is overcome by dopamine rceptor-1 agonist[2]. Kinase Assay GSK-3 activity is assayed in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 1 mM EGTA, and 1 mM EDTA buffer, at 37°C, in the presence of 15 μM GS-1 (substrate), 15 μM [γ-32P]ATP in a final volume of 12 μL. After 20 min incubation at 37°C, 4 μL aliquots of the supernatant are spotted onto 2×2 cm pieces of Whatman P81 phosphocellulose paper, and 20 s later, the filters are washed four times (for at least 10 min each time) in 1% phosphoric acid. The dried filters are transferred into scintillation vials, and the radioactivity is measured in a liquid scintillation counter. Blank values are subtracted, and the GSK-3β activity is expressed in picomoles of phosphate incorporated in GS-1 per 20 min or in percentage of maximal activity[1]. Animal Admin Apomorphine hydrochloride is administered (0.5 mg/kg). L-dopa (25 mg/kg) plus benserazide-HCl (6.25 mg/kg) are given once-daily. TDZD8, a non-ATP competitive inhibitor of GSK-3β, is dissolved in 10% DMSO and is administered i.p. (TDZD8-L group, 1 mg/kg; TDZD8-H group, 2 mg/kg, respectively) 30 min prior to L-dopa intake for 3 weeks. (±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride (SKF38393), a D1 Dopamine receptor agonist, is dissolved in saline and is administered i.p. (SKF38393-L group, 5 mg/kg; SKF38393-H group, 10 mg/kg, respectively) 30 min prior to L-dopa intake for 3 weeks[2]. References [1]. Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45(6):1292-9. [2]. Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527. [3]. Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76(2):172-83. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 335.5±35.0 °C at 760 mmHg Melting Point 63-64.4ºC Molecular Formula C10H10N2O2S Molecular Weight 222.264 Flash Point 156.7±25.9 °C Exact Mass 222.046295 PSA 72.24000 LogP 0.30 Vapour Pressure 0.0±0.7 mmHg at 25°C Index of Refraction 1.646 InChIKey JDSJDASOXWCHPN-UHFFFAOYSA-N SMILES Cn1sc(=O)n(Cc2ccccc2)c1=O Storage condition 2-8°C Water Solubility DMSO: 18 mg/mL |
| Use of | Properties Name 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione Synonym More Synonyms TDZD-8 Biological Activity Related Catalog Signaling Pathways >> PI3K/Akt/mTOR >> GSK-3 Signaling Pathways >> Stem Cell/Wnt >> GSK-3 Research Areas >> Cancer GSK-3β:2 μM (IC50) References [1]. Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45(6):1292-9. [2]. Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527. [3]. Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76(2):172-83. Chemical & Physical Properties Molecular Formula C10H10N2O2S Exact Mass 222.046295 PSA 72.24000 Index of Refraction 1.646 InChIKey JDSJDASOXWCHPN-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 4-BENZOYL-3-HYDROXYPHENYL 2-((4-BENZOYL-3-HYDROXYPHENOXY)METHYLENE)PENTANEPEROXOATE | 103637-50-9 | 2A-0137050 |
| 4-BENZOYLPHTHALIC ACID | 3885-88-9 | 2A-0137054 |
| 4-BENZYL-1-BROMOISOQUINOLIN-3-AMINE | 13130-81-9 | 2A-0137064 |
| 4-BENZYL-2-(2-(DIMETHYLAMINO)ETHYL)PHTHALAZIN-1(2H)-ONE | 16188-61-7 | 2A-0137069 |
| 4-BENZYL-2-(2-(DIMETHYLAMINO)ETHYL)PHTHALAZIN-1(2H)-ONE HYDROCHLORIDE | 16188-76-4 | 2A-0137070 |
| 4-BENZYL-5-OXOTETRAHYDRO-2H-PYRAN-3-CARBOXAMIDE | 433283-16-0 | 2A-0137084 |
| 4-BENZYLBENZONITRILE | 23450-31-9 | 2A-0137095 |
| 4-BENZYLIDENE-2-PHENYL-2-OXAZOLIN-5-ONE | 17606-70-1 | 2A-0137097 |
| 4-BENZYLMORPHOLIN-2-ONE | 5453-99-6 | 2A-0137099 |
| 4-BENZYLOXAZOLIDINE-2,5-DIONE | 583-47-1 | 2A-0137104 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS